



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ashkenazi, et al. Docket No.: 39780-1618P2C17
Serial No.: 09/904,838 Group Art Unit: 1647
Filing Date: July 13, 2001 Examiner: Romeo, David S.
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --

CERTIFICATE OF MAILING (37 CFR 1.8(a))

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: December 2, 2003

Cheryl Ann Rogers
Cheryl Ann Rogers

12/06/2003 RHEBHT 0000122 081641 09904838

01 FC:1806 180.00 DA


- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☒ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39780-1618P2C17).

Respectfully submitted,

Dated: December 2, 2003

By: Daphne Reddy
Daphne Reddy
Reg. No. 53,507


HELLER EHRMAN WHITE & MCAULIFFE LLP
Customer No. 35489
275 Middlefield Road
Menlo Park, CA 94025-3506
Telephone: (650) 324-7000
Facsimile: (650) 324-0638

| | | |
|---|--|---|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PTO-1449  | ATTY. DOCKET NO.: 39780-16182C17 | SERIAL NO.: 09/904,838 |
| | APPLICANT : Ashkenazi, et al. | |
| | FILING DATE: 7/13/01 | GROUP: 1647 |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
| | Ashkenazi, et al., "Novel isolated PRO polypeptides, e.g. PRO245 and PRO1868, useful for treating e.g. Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, cancer, neuropathies, diabetes and psoriasis", P_ACD23222; Patent: US2003064367-A1, filed July 13, 2001; Publication Date: April 3, 2003. | |
| | Ashkenazi, et al., "New PRO polypeptides and nucleic acid molecules, useful in diagnosing or treating inflammatory diseases, organ failure, atherosclerosis, cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's disease", P_ABX71541; Patent: US2002132240-A1; filed July 18, 2001; Publication Date: September 19, 2002. | |
| | Ashkenazi, et al., "Novel secreted and transmembrane polypeptides for modulating biological activity of cell expressing the polypeptide, identifying agonists or antagonists of polypeptides, and as molecular weight markers", P_ACD20098; Patent: US2003036060-A1; filed July 12, 2001; Publication Date: February 20, 2003. | |
| | Ashkenazi, et al., "Sixty one nucleic acids encoding PRO polypeptides which are useful in the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung squamous cell carcinoma) and Neurodegenerative diseases (e.g. Alzheimer's disease)", P_AAF72392; Patent: WO200104311-A1; filed February 22, 2000; Publication Date: January 18, 2001. | |
| | Botstein, et al., "New antibody that binds to a PRO polypeptide, e.g. PRO187 and PRO533, useful for diagnosing and treating cancers", P_AAF60376; Patent: WO200105836-A1; filed December 20, 1999; Publication Date: January 25, 2001. | |
| | Goddard, et al., "New isolated antibodies which bind to specific polypeptides used for diagnosis and treatment of neoplastic cell growth and proliferation", P_AAA30056; Patent: WO200015666-A2; filed September 8, 1999; Publication Date: March 23, 2000. | |
| | Botstein, et al., "Antibodies against specific proteins overexpressed in tumors", P_AAX28437; Patent: WO9914327-A2; filed September 10, 1998; Publication Date: March 25, 1999. | |
| | Chen, et al., "New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration", P_AAX52234; Patent: WO9914328-A2; filed September 16, 1998; Publication Date: March 25, 1999. | |
| | Ashkenazi, et al., "New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 and PRO1868, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy", P_ACA58386; Patent: US2002192659-A1; filed July 10, 2001; Publication Date: December 19, 2002. | |
| | Ashkenazi, et al., "New transmembrane polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy, in chromosome identification, as chromosome markers, in generating probes and in tissue typing", P_ACA60093; Patent: US2003003530-A1; filed July 11, 2001; Publication Date: January 2, 2003. | |
| | Ashkenazi, et al., "Sixty one isolated nucleic acids encoding a PRO polypeptide, e.g. PRO245 or PRO1868, useful in chromosome and gene mapping, in generating antisense RNA and DNA, and in treating cancer and Alzheimer's disease", P_ACA05431; Patent: US2003023054-A1; filed July 16, 2001; Publication Date: January 0, 2003. | |
| EXAMINER | DATE CONSIDERED | |


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|--|----------------------------------|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PTO-1449 | ATTY. DOCKET NO.: 39780-16182C17 | SERIAL NO.: 09/904,838 |
| | APPLICANT : Ashkenazi, et al. | |
| | FILING DATE: 7/13/01 | GROUP: 1647 |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
| | Ashkenazi, et al., "New secreted and transmembrane PRO polypeptides (e.g. PRO533 or PRO245) and genes encoding them, useful for detecting or treating e.g. hyperplasia, endometriosis, cancers, ischemia, coronary arterial disease or inflammations", P_ABX96110; Patent: US2002160374-A1; filed July 12, 2001; Publication Date: October 31, 2002. | |
| | Ashkenazi, et al., "Isolated nucleic acid useful for e.g. treating pathological disorders encodes a secreted or transmembrane protein", P_ACA58989; Patent: US2002146709-A1; filed July 18, 2001; Publication Date: October 10, 2002. | |
| | Ashkenazi, et al., "Novel secreted and transmembrane polypeptides and polynucleotides encoding them useful for treating abnormal bleeding involved in gynecological diseases, skin disease and neurodegenerative diseases", P_ACD19736; Patent: US2003027143-A1; filed July 16, 2001; Publication Date: February 6, 2003. | |
| | Ashkenazi, et al., "New PRO polypeptides and nucleic acid molecules, useful in diagnosing or treating inflammatory diseases, organ failure, atherosclerosis, cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's disease", P_ACA54901; Patent: US2003017463-A1; filed July 11, 2001; Publication Date: January 23, 2003. | |
| | Ashkenazi, et al., "New genes and secreted and transmembrane polypeptides (e.g. PRO245 or PRO335), useful for treating or diagnosing e.g. Alzheimer's disease, cancers, hemorrhage, rheumatoid arthritis, diabetes, cirrhosis, ischemia or strokes", P_ACD07493; Patent: US2002197671-A1; filed July 17, 2001; Publication Date: December 26, 2002. | |
| | Ashkenazi, et al., "Novel secreted and transmembrane polypeptide for modulating biological activity of cell expressing the polypeptide, identifying agonists or antagonists of polypeptide, and as molecular weight markers", P_ACD23584; Patent: US2003064923-A1; filed July 13, 2001; Publication Date: April 3, 2003. | |
| | Clark, et al., "The Secreted Protein Discovery Initiative (SPDI), a Large-Scale Effort to Identify Novel Human Secreted and Transmembrane Proteins: A bioinformatics Assessment" AY358873; Genome Res. 13 (10), 2265-2270 (2003) direct submission submitted August 1, 2003. | |
| | Botstein, et al., "Polypeptidic compositions and methods for the treatment of tumors", AX076929; Patent WO0105836-A 41, filed January 25, 2001. | |
| | Ashkenazi, et al., "Secreted and transmembrane polypeptides and nucleic acids encoding the same", AX697522; Patent WO0104311-A 113, filed January 18, 2001. | |
| | Wood, et al., "Secretory and transmembrane polypeptides and nucleic acid encoding the same", BD075461; Patent: JP2001516580-A 94, filed October 2, 2001. | |
| | Wood, et al., "Secreted and transmembrane polypeptides and nucleic acids encoding the same", BD172321; Patent: JP2002223786-A 94, filed August 13, 2002. | |
| | Wood, et al., "Secreted and transmembrane polypeptides and nucleic acids encoding the same", BD172640; Patent: JP2002238586-A 94, filed August 27, 2002. | |
| EXAMINER | DATE CONSIDERED | |


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|--|---|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PTO-1449  | ATTY. DOCKET NO.: 39780-16182C17 | SERIAL NO.: 09/904,838 |
| | APPLICANT : Ashkenazi, et al. | |
| | FILING DATE: 7/13/01 | GROUP: 1647 |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
| | Wood, et al., "Secreted and transmembrane polypeptides and nucleic acids encoding the same", BD172959; Patent: JP2002238587-A 94, filed August 27, 2002. | |
| | Wood, et al., "Secreted and transmembrane polypeptides and nucleic acids encoding the same", BD173278; Patent: JP2002238588-A 94, filed August 27, 2002. | |
| | Wood, et al., "Secreted and transmembrane polypeptides and nucleic acids encoding the same", BD175312; Patent: JP2002253280-A 94, filed September 10, 2002. | |
| | Yashiro, et al., "Distinct transcriptional regulation and phylogenetic divergence of human LEFTY genes", NM_020997, <i>Genes Cells</i> 5 (5), pp. 343-357 (2000). | |
| | Kosaki, et al., "Characterization and mutation analysis of human LETY A and LEFTY B, homologues of murine genes implicated in left-right axis development, NM_020997, <i>Am. J. Hum. Genet.</i> 64 (3), pp. 712-721 (1999). | |
| | Strausberg, R., direct submission (April 8, 2002) to National Institutes of Health, Mammalian Gene Collection (MG), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590; BC027883. | |
| | Ebner, et al., "Novel Nodal and Lefty polypeptides useful for diagnosing or treating cell growth and differentiation related disorders in humans, e.g. cancer, autoimmunity, arthritis and immunosuppression", P_AAD45128; Patent: US2002086351-A1; filed August 20, 1998; Publication Date: July 4, 2002. | |
| | Ebner, et al., "New isolate human Nodal and Lefty polypeptides", P_AAX31925; Patent: WO9909198-A1; filed August 20, 1998; Publication Date: February 25, 1999. | |
| | Birse, et al., "Isolated nucleic acid molecules encoding novel ovarian polypeptides, useful in the prevention, treatment and diagnosis of cancer (e.g. ovarian cancer), immune disorders, cardiovascular disorders and neurological diseases", P_ABQ55009; Patent: WO200200677-A1; filed June 7, 2001; Publication Date: January 3, 2002. | |
| | Ashkenazi, et al., "New PRO polypeptides and nucleic acid molecules, useful in atherosclerosis, cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's disease", P_ABU54366; Patent: US2002132240-A1; filed July 18, 2001; Publication Date: September 19, 2002. | |
| | Ashkenazi, et al., "New secreted and transmembrane PRO polypeptides (e.g. PRO533 or PRO245) and genes encoding them, useful for detecting or treating e.g. hyperplasia, endometriosis, cancers, ischemia, coronary arterial disease or inflammations", P_ABU64518; Patent: US2002160374-A1; filed July 12, 2001; Publication Date: October 31, 2002. | |
| | Ashkenazi, et al., "Sixty one isolated nucleic acids encoding a PRO polypeptide, e.g. PRO245 or PRO1868, useful in chromosome and gene mapping, in generating antisense RNA and DNA, and in treating cancer and Alzheimer's disease", P_ABU67364; Patent: US2003023054-A1; filed July 16, 2001; Publication Date: January 30, 2003. | |
| EXAMINER | DATE CONSIDERED | |


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|---|---|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PTO-1449  | ATTY. DOCKET NO.: 39780-16182C17 | SERIAL NO.: 09/904,838 |
| | APPLICANT : Ashkenazi, et al. | |
| | FILING DATE: 7/13/01 | GROUP: 1647 |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
| | Ashkenazi, et al., "New transmembrane polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy, in chromosome identification, as chromosome markers, in generating probes and in tissue typing", P_ABU71910; Patent: US2003003530-A1; filed July 11, 2001; Publication Date: January 2, 2003. | |
| | Ashkenazi, et al., "New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 or PRO1868, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy", P_ABU71464; Patent: US2002192659-A1; filed July 10, 2001; Publication Date: December 19, 2002. | |
| | Ashkenazi, et al., "New PRO polypeptides and nucleic acid molecules, useful in diagnosing or treating inflammatory diseases, organ failure, atherosclerosis, cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's disease", P_ABU69641; Patent: US2003017463-A1; filed July 11, 2001; Publication Date: January 23, 2003. | |
| | Ashkenazi, et al., "Isolated nucleic acid useful for e.g. treating pathological disorders encodes a secreted or transmembrane protein", P_ABU71609; Patent: US2002146709-A1; filed July 18, 2001; Publication Date: October 10, 2002. | |
| | Ashkenazi, et al., "New genes and secreted and transmembrane polypeptides (e.g. PRO245 or PRO335), useful for treating or diagnosing e.g. Alzheimer's disease, cancers, hemorrhage, rheumatoid arthritis, diabetes, cirrhosis, ischemia or strokes", P_ABO01793; Patent: US2002197671-A1; filed July 17, 2001; Publication Date: December 26, 2002. | |
| | Ashkenazi, et al., "Novel secreted and transmembrane polypeptides and polynucleotides encoding them useful for treating abnormal bleeding involved in gynecological diseases, skin disease and neurodegenerative diseases", P_ABO14823; Patent: US2003027143-A1; filed July 16, 2001; Publication Date: February 6, 2003. | |
| | Ashkenazi, et al., "Novel secreted and transmembrane polypeptide for modulating biological activity of cell expressing the polypeptide, identifying agonists or antagonists of polypeptide, and as molecular weight markers", P_ABO17574; Patent: US2003064923-A1; filed July 13, 2001; Publication Date: April 3, 2003. | |
| | Ashkenazi, et al., "Novel isolated PRO polypeptides, e.g. PRO245 and PRO1868, useful for treating e.g. Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, cancer, neuropathies, diabetes and psoriasis", P_ABO17513; Patent: US2003064367-A1, filed July 13, 2001; Publication Date: April 3, 2003. | |
| | Ashkenazi, et al., "Novel secreted and transmembrane polypeptides for modulating biological activity of cell expressing the polypeptide, identifying agonists or antagonists of polypeptides, and as molecular weight markers", P_ABO14884; Patent: US2003036060-A1; filed July 12, 2001; Publication Date: February 20, 2003. | |
| | Monahan, et al., "Assessing whether a patient is afflicted with ovarian cancer, useful comparing the expression level of a cancer marker in a sample from a patient and from a non cancer patient", P_ABG96362; Patent: WO200271928-A2; filed March 14, 2002; Publication Date: September 19, 2002. | |
| EXAMINER | DATE CONSIDERED | |


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|---|----------------------------------|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PTO-1449  | ATTY. DOCKET NO.: 39780-16182C17 | SERIAL NO.: 09/904,838 |
| | APPLICANT : Ashkenazi, et al. | |
| | FILING DATE: 7/13/01 | GROUP: 1647 |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
| | Ebner, et al., "Novel Nodal and Lefty polypeptides useful for diagnosing or treating cell growth and differentiation related disorders in humans, e.g. cancer, autoimmunity, arthritis and immunosuppression", P_AAE28182; Patent: US2002086351-A1; filed August 20, 1998; Publication Date: July 4, 2002. | |
| | Ashkenazi, et al., "Sixty one nucleic acids encoding PRO polypeptides which are useful in the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung squamous cell carcinoma) and Neurodegenerative diseases (e.g. Alzheimer's disease)", P_AAB80231; Patent: WO200104311-A1; filed February 22, 2000; Publication Date: January 18, 2001. | |
| | Botstein, et al., "New antibody that binds to a PRO polypeptide, e.g. PRO187 and PRO533, useful for diagnosing and treating cancers", P_AAB68600; Patent: WO200105836-A1; filed December 20, 1999; Publication Date: January 25, 2001. | |
| | Goddard, et al., "New isolated antibodies which bind to specific polypeptides used for diagnosis and treatment of neoplastic cell growth and proliferation", P_AAY88575; Patent: WO200015666-A2; filed September 8, 1999; Publication Date: March 23, 2000. | |
| | Botstein, et al., "Antibodies against specific proteins overexpressed in tumors", P_AAY05287; Patent: WO9914327-A2; filed September 10, 1998; Publication Date: March 25, 1999. | |
| | Ebner, et al., "New isolate human Nodal and Lefty polypeptides", P_AAY03850; Patent: WO9909198-A1; filed August 20, 1998; Publication Date: February 25, 1999. | |
| | Chen, et al., "New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration", P_AAY13363; Patent: WO9914328-A2; filed September 16, 1998; Publication Date: March 25, 1999. | |
| | Kosaki, et al, Direct submission (August 1, 1998) Department of Pathology, Baylor College of Medicine, One Baylor Plaza S230, Houston, TX 77030; AAD48144; Accession: AF081512. | |
| | Strausberg, R., Direct submission (April 8, 2002) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590; AAH27883; Accession: BC027883. | |
| | Kosaki, et al, Direct submission (August 3, 1998) Department of Pathology, Baylor College of Medicine, One Baylor Plaza S230, Houston, TX 77030; AAC33967; Accession: AF081507. | |
| | Clark, et al., direct submission (August 1, 2003) Department of Bioinformatics, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080; AAQ89232; Accession: AY358873. | |
| | Kosaki, et al., "Characterization and mutation analysis of human LEFTY A and LEFTY B, homologues of murine genes implicated in left-right axis development", NP_066277; Accession: NM_020997; <i>Am. J. Hum. Gen.</i> 66, 712-721 (1999). | |
| | Kosaki, et al., "Characterization and mutation analysis of human LEFTY A and LEFTY B, homologues of murine genes implicated in left-right axis development", Accession: 075610; <i>Am. J. Hum. Gen.</i> 66, 712-721 (1999). | |
| EXAMINER | DATE CONSIDERED | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|--|---|----------------------------------|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  PTO-1449 | ATTY. DOCKET NO.: 39780-16182C17 | SERIAL NO.: 09/904,838 |
| | APPLICANT : Ashkenazi, et al. | |
| | FILING DATE: 7/13/01 | GROUP: 1647 |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
| | Celeste, et al., "New Purified bone morphogenic protein-17 and -18 (BMP-17 and BMP-18) polypeptides, useful or the induction of growth and/or differentiation of undifferentiated embryonic and stem cells", P_AAY17870; Patent: WO9929718-A2; filed November 17, 1998; Publication Date: June 17, 1999. | |
| | Tabibzadeh, et al., "Inhibiting the activity of transforming growth factor (TGF) beta, for treating e.g. fibrosis, comprises contacting tissue expressing TGF beta with ebaf peptide or its analogue", P_AAU79519; Patent: WO200229105-A1; filed October 3, 2001; Publication Date: April 11, 2002; Accession: P_AAU79519 | |
| | Tabibzadeh, et al., "Inducing growth and enhancing survival of nervous tissue by contacting with endometrial bleeding associated factor protein", P_AAB19837; Patent: WO200066068; filed April 28, 2000; Publication Date: November 9, 2000; Accession: P_AAB19837. | |
| | Ota, et al., "Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs", P_AAB95157; Patent Number: EP1074617-A2, filed July 28, 2000; Publication Date: February 7, 2001; Accession: P_AAB95157. | |
| | Celeste, et al., "New Purified bone morphogenic protein-17 and -18 (BMP-17 and BMP-18) polypeptides, useful or the induction of growth and/or differentiation of undifferentiated embryonic and stem cells", P_AAY17871; Patent: WO9929718-A2; filed November 17, 1998; Pubicate Date: June 17, 1999; Accession: P_AAY17871. | |
| | Kosaki, et al., direct submission (August 1, 1998) Department of Pathology, Baylor College of Medicine, One Baylor Plaza, S230, Houston, TX 77030; AAD48145; Accession: AF081513. | |
| | Strausberg, R., direct submission (July 31, 2002) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590; AAH35718; Accession: BC035718. | |
| | Bassi, et al., Direct submission (August 3, 1998) Department of Pathology, Baylor College of Medicine, One Baylor Plaza, S230, Houston, TX 77030; AAC32600; Accession: AF081511. | |
| | Kothapalli, et al., "Detection of ebaf, a novel human gene of the transforming growth factor beta superfamily association of gene expression with endometrial bleeding", NP_003231; Accession: NM_003240; <i>J. Clin. Invest.</i> 99 (10), 2342-2350 (1997). | |
| | Kothapalli, et al., "Detection of ebaf, a novel human gene of the transforming growth factor beta superfamily association of gene expression with endometrial bleeding", TGF4_HUMAN; Accession: 000292; 075611; <i>J. Clin. Invest.</i> 99 (10), 2342-2350 (1997). | |
| | Isogai, et al., "direct submission (March 20, 2002) Takao Isogai, Helix Research Institute, Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan; BAC11556; Accession: AK075344. | |
| EXAMINER | DATE CONSIDERED | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|--|---|----------------------------------|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  | ATTY. DOCKET NO.: 39780-16182C17 | SERIAL NO.: 09/904,838 |
| | APPLICANT : Ashkenazi, et al. | |
| | FILING DATE: 7/13/01 | GROUP: 1647 |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
| | Tabibzadeh, et al., "Inhibiting the activity of transforming growth factor (TGF) beta, for treating e.g. fibrosis, comprises contacting tissue expressing TGF beta with ebaf peptide or its analogue", P_AAU79521; Patent: WO200229105-A1; filed October 3, 2001; Publication Date: April 11, 2002; Accession: P_AAU79521. | |
| | Tabibzadeh, et al., "Inhibiting the activity of transforming growth factor (TGF) beta, for treating e.g. fibrosis, comprises contacting tissue expressing TGF beta with ebaf peptide or its analogue", P_AAU79520; Patent: WO200229105-A1; filed October 3, 2001; Publication Date: April 11, 2002; Accession: P_AAU79520. | |
| | Wang, et al., "Treating a subject with a disorder resulting from insufficient insulin production, and inducing outgrowth of pancreatic cells, involves using a transforming growth factor beta therapeutic", P_AAU77104; Patent: WO200212336-A2; filed February 9, 2001; Publication Date: February 14, 2002; Accession: P_AAU77104. | |
| | Weintraub, et al., "New mutant cystine knot growth factor proteins comprising one or more mutant subunits, useful for treating or preventing diseases e.g. hypothyroidism and thyroid cancer", P_AAY92013; Patent: WO200017360-A1; filed March 19, 1999; Publication Date: March 30, 2000; Accession: P_AAY92013. | |
| | Tabibzadeh, et al., direct submission (December 9, 1996) Pathology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612; AAB53269; Accession: U81523. | |
| | Edmonds, et al., "Novel polypeptides and polynucleotides of secreted proteins useful for treating various diseases such as multiple sclerosis, cancer, autoimmune diseases, osteoporosis, Alzheimer's disease and Parkinson's disease", P_AAU91323; Patent: WO200214358-A2; filed July 30, 2001; Publication Date: February 21, 2002; Accession: P_AAU91323. | |
| | Edmonds, et al., "Novel secreted proteins and their uses", CAD29027; Patent: WO0214358-A1, filed February 21, 2002; Accession: AX392959. | |
| | Birse, et al., "Isolated nucleic acid molecules encoding novel ovarian polypeptides, useful in the prevention, treatment and diagnosis of cancer (e.g. ovarian cancer), immune disorders cardiovascular disorders and neurological diseases", P_ABP41932; Patent: WO200200677-A1; filed June 7, 2001; Publication Date: January 3, 2002; Accession: P_ABP41932. | |
| | | |
| | | |
| EXAMINER | DATE CONSIDERED | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.